Core Viewpoint - The announcement highlights the positive clinical trial results for LuX-Valve Plus and Ken-Valve, indicating the potential of these products to meet significant unmet clinical needs in the market [1] Group 1: Clinical Trial Results - The global multicenter clinical trial ("TRINITY") for LuX-Valve Plus has shown promising 6-month follow-up results for patients with large annuli [1] - Ken-Valve has demonstrated 1-year follow-up results in large annuli patients, further supporting the efficacy of the company's products [1] Group 2: Market Implications - The results are expected to showcase the advantages of the company's products in addressing a wide range of unmet clinical needs, potentially expanding their market reach [1]
健世科技-B(09877.HK)：LuX-Valve Plus及Ken-Valve大瓣环临床数据于2025年伦敦瓣膜会发布，展现产品独特大尺寸优势